JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

Home・Lista de Ações・CytoSorbents Corp
Search

CytoSorbents Corp

Abrir

SetorSaúde

0.6

Neutro

Atualização de preço 1 de mai. de 2026, 19:59 UTC

ComprarVender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.6

Máximo

0.62

Indicadores-chave

By Trading Economics

Rendimento

-2.3M

-5.5M

Vendas

-251K

9.2M

Margem de lucro

-59.526

Funcionários

129

EBITDA

-766K

-3.7M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+20.97% upside

Dividendos

By Dow Jones

Próximos Ganhos

13 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-3.9M

38M

Abertura anterior

0.6

Fecho anterior

0.6

Sentimento de Notícias

By Acuity

50%

50%

176 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.705 / 0.771 Suporte e Resistência

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de mai. de 2026, 22:17 UTC

Ganhos

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Ler

4 de mai. de 2026, 23:47 UTC

Ganhos

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Ler

4 de mai. de 2026, 23:45 UTC

Ganhos

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Ler

4 de mai. de 2026, 23:45 UTC

Ganhos

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Ler

4 de mai. de 2026, 23:40 UTC

Conversa de Mercado

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Ler

4 de mai. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Ler

4 de mai. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Ler

4 de mai. de 2026, 22:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Ler

4 de mai. de 2026, 22:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Ler

4 de mai. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Ler

4 de mai. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Ler

4 de mai. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Shareholders to Own About 51% of Combined Company

DJ

Ler

4 de mai. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Ler

4 de mai. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Deal Unanimously Recommended by Vault Board

DJ

Ler

4 de mai. de 2026, 22:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Ler

4 de mai. de 2026, 22:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Ler

4 de mai. de 2026, 22:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Ler

4 de mai. de 2026, 22:37 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Ler

4 de mai. de 2026, 22:26 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Ler

4 de mai. de 2026, 22:02 UTC

Ganhos

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Ler

4 de mai. de 2026, 22:00 UTC

Conversa de Mercado

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Ler

4 de mai. de 2026, 21:52 UTC

Ganhos

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Ler

4 de mai. de 2026, 21:50 UTC

Ganhos

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Ler

4 de mai. de 2026, 21:50 UTC

Ganhos

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Ler

4 de mai. de 2026, 21:49 UTC

Ganhos

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Ler

4 de mai. de 2026, 21:44 UTC

Ganhos

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Ler

4 de mai. de 2026, 21:44 UTC

Ganhos

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Ler

4 de mai. de 2026, 21:43 UTC

Ganhos

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Ler

4 de mai. de 2026, 21:41 UTC

Ganhos

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Ler

4 de mai. de 2026, 21:40 UTC

Ganhos

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Ler

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

20.97% parte superior

Previsão para 12 meses

Média 0.75 USD  20.97%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.705 / 0.771Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

All events are bearish.

Médio Prazo

Very Strong Bearish Evidence

All events are bearish.

Longo Prazo

Bearish Evidence

All events are bearish.

Sentimento

By Acuity

176 / 347 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Outras ações do setor

JNJ

Johnson and Johnson

225.55

↑ +0.06%

UNH

UnitedHealth Group Inc

364.08

↓-1.27%

TMO

Thermo Fisher Scientific Inc

465.22

↑ +0.09%

ISRG

Intuitive Surgical Inc

452.75

↑ +0.48%

ABT

Abbott Laboratories

87.25

↓-1.3%
help-icon Live chat